spacer
home > > winter 2003 > central laboratories and the importance of an effective quality system
PUBLICATIONS


Central Laboratories and the Importance of an Effective Quality System

Central laboratories play a significant role in the clinical trials process by providing drug development companies with clean, combinable laboratory data, which can be analysed and reported in a timely and cost-effective manner, and which can undergo global regulatory review. Due to the critical nature of the data being generated, it is essential that data are accurate, reliable and reproducible.

So, how can a central laboratory assure its clients of the quality of the data being generated in its operation? The answer lies in the question: the laboratory must establish a quality assurance system. Establishing a quality system involves the implementation of a series of processes and procedures that standardise operations. For a quality system to be credible, it must be examined by an independent external party that is recognised as being competent in the assessment of such a system. These external parties will investigate the laboratory's compliance to a recognised quality standard or guideline and make a recommendation for registration.

There are many different quality standards and guidelines in existence that are recognised in industry. For central laboratories, some quality standards are compulsory depending on the location of operations, whilst other standards are optional and may be adopted by laboratories wishing to enhance their reputation for quality. All central laboratories based in the US are obliged to meet clinical laboratory improvement amendment (CLIA) and state requirements. Additionally, US laboratories, as well as any medical laboratory that handles patient samples which originate in the US, can choose to comply with the requirements of the College of American Pathologists (CAP). In Europe, Asia and Australasia, laboratories will typically aim to comply with the standards published by the International Organization for Standardization (ISO), or with good laboratory practice (GLP) requirements.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Clare O'Sullivan, Laboratory Manager at ICON Laboratories

Clare O'Sullivan is the Laboratory Manager at ICON Laboratories, Europe. She holds a BSc (Hons) and a Masters degree in Microbiology from the National University of Ireland, Cork. Prior to becoming Laboratory Manager, Clare worked as QA Manager for over four years in ICON Laboratories and Tibotec-Virco Ireland, now a division of Johnson and Johnson. During her career as QA Manager she gained experience in the implementation and maintenance of quality systems compliant with ISO 17025, CAP, EN45001, EN45004 and CLIA regulations in both European and US-based facilities.

spacer
Clare O'Sullivan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement